These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 16640524

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.
    Transplantation; 2007 Apr 15; 83(7):912-8. PubMed ID: 17460562
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA.
    Cancer; 2005 Oct 15; 104(8):1661-7. PubMed ID: 16149091
    [Abstract] [Full Text] [Related]

  • 5. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
    Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA.
    Transplantation; 2006 Aug 15; 82(3):375-81. PubMed ID: 16906036
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M, Ogita K, Matsuura T, Takahashi Y, Nishimoto Y, Ohga S, Hara T, Soejima Y, Taketomi A, Maehara Y, Kohashi K, Tsuneyoshi M, Taguchi T.
    Pediatr Transplant; 2007 Sep 15; 11(6):671-5. PubMed ID: 17663692
    [Abstract] [Full Text] [Related]

  • 9. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z, Amlot P, Lachmanan SR, Tur-Kaspa R, Rolles K, Burroughs AK.
    Liver Transpl Surg; 1999 May 15; 5(3):184-91. PubMed ID: 10226108
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct 15; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 11. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
    Kaczmarek I, Beiras-Fernandez A, Sadoni S, Bengel D, Deutsch MA, Meiser B, Reichart B.
    Exp Clin Transplant; 2005 Dec 15; 3(2):381-4. PubMed ID: 16417448
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
    Ann Hematol; 2006 Jul 15; 85(7):478-84. PubMed ID: 16586109
    [Abstract] [Full Text] [Related]

  • 13. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.
    Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C.
    N Engl J Med; 1991 May 23; 324(21):1451-6. PubMed ID: 2023604
    [Abstract] [Full Text] [Related]

  • 14. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC.
    J Clin Oncol; 2005 Sep 20; 23(27):6481-8. PubMed ID: 16170157
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
    Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ, Homan van der Heide JJ, Veeger NJ, Kluin PM, Kluin-Nelemans HC.
    Clin Transplant; 2005 Jun 20; 19(3):327-34. PubMed ID: 15877793
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb 20; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.
    Raj R, Frost AE.
    J Heart Lung Transplant; 2005 Jun 20; 24(6):671-9. PubMed ID: 15949726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.